Normosang (Human Hemin)

Human Hemin, the active ingredient in Normosang, is a heme preparation presented as an injectable solution for intravenous use. It is employed to treat acute intermittent porphyria and related acute hepatic porphyria attacks in patients experiencing neurovisceral crises.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide. The company ensures full regulatory compliance, quality assurance and cold‑chain logistics for this injectable product. Normosang is distributed to both public and private healthcare institutions, supporting rapid access during emergency porphyria episodes.

Normosang is used in the management of acute intermittent porphyria, a disorder of heme biosynthesis. Acute intermittent porphyria: reduces accumulation of neurotoxic porphyrin precursors and alleviates acute neurovisceral symptoms. Acute hepatic porphyria: provides heme feedback inhibition to control attacks in related hepatic porphyrias. Porphyria attacks: shortens duration of severe abdominal pain, nausea and neurological manifestations during an acute episode.

Normosang may be associated with a range of adverse reactions, varying from mild infusion‑related events to rare serious complications.

Common Side Effects: - Infusion site pain - Phlebitis or erythema at injection site - Nausea - Vomiting - Headache - Fever or chills

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reaction - Hemolysis leading to dark urine - Acute renal failure - Coagulopathy or bleeding disorders - Severe hypotension - Thrombocytopenia

When using Normosang, clinicians should observe specific precautions to minimize risks and ensure safe administration. - Monitor liver function: assess hepatic enzymes before and during therapy. - Monitor renal function: evaluate creatinine and urine output regularly. - Assess for hypersensitivity: obtain allergy history and observe for signs of reaction during infusion. - Avoid use in patients with known severe hepatic or renal impairment unless benefits outweigh risks. - Use under specialist supervision: administration should be directed by physicians experienced in porphyria management. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Normosang can interact with other medicines, influencing its safety or effectiveness.

Major Interactions (Avoid): - Concomitant use with porphyrinogenic drugs (e.g., barbiturates, sulfonamides) may precipitate attacks. - Co‑administration with strong CYP inducers (e.g., rifampin) may reduce hemin efficacy. - Simultaneous use with other heme preparations can increase risk of iron overload.

Moderate Interactions (Monitor Closely): - Anticoagulants: hemin may enhance anticoagulant effect, requiring INR monitoring. - Other intravenous iron products: combined use may affect iron balance. - Hypotensive agents: additive blood pressure lowering effect may occur. - Diuretics: monitor electrolytes as hemin infusion can influence fluid status.